Complain about a product or service

FDA Refuses to Approve Pfizer Cox-2 Drug

April 8, 2005
The Food and Drug Administration has refused to approve a liquid Cox-2 painkiller application submitted by Pfizer. The FDA did not cite its reasons for issuing the "non-approval" letter for Pfizer's parecoxib sodium, marketed in Europe and elsewhere Dynastat.

Related Stories • Researchers Claim Vioxx Safety Study Was Actually Marketing Plan • First Vioxx Judgment Overturned On Appeal • Merck Agrees to Pay $58 Million to Settle Vioxx Claims • Researchers Claim Merck Cooked Vioxx Data • Common Pain Relievers May Boost Muscle Mass • More Painkillers Can Cause More Pain • Merck Caves, Agrees To $4.85 Billion Vioxx Settlement • New York Sues Vioxx Maker over Drug’s Risks • Merck Wins Vioxx Case In Illinois • Judge Rules Out Vioxx "Super" Class Action • FDA Critic Blasts Merck's Vioxx Replacement • Merck Loses New Orleans Vioxx Case • Merck Wins Latest Vioxx Suit • Vioxx Study Authors Backtrack On Claim • Older Painkillers May Increase Heart Attack Risk • More about Vioxx --- Other NSAIDs • Bextra • Celebrex • Dangers of Other Vioxx-Type Drugs • Vioxx Alternatives • Aleve Ingredient Seen as Health Risk

Pfizer said it plans to appeal the rejection. It argues that Dynastat reduces the need for opioids to control pain after surgical procedures. The company noted that European regulators had found that the Cox-2 class of drugs provided benefits that outweigh their risks.

Merck pulled its Cox-2 drug, Vioxx, off the market in September 2004, saying it was "putting patient safety first" but the Wall Street Journal reported earlier that company officials had fought for years to protect the highly profitable drug and to keep news of the health risks quiet.

The FDA estimates that Vioxx may have contributed to 27,785 heart attacks and sudden cardiac deaths between 1999 and 2003. The estimate is based on the number of prescriptions issued for Vioxx between 1999 and 2003.

In August, a Texas jury awarded the widow of a Vioxx user who died from a heart arrhythmia $253.4 million. The second of what is likely to be many Vioxx-related trials got underway this week in Atlantic City, N.J.

Pfizer's two Cox-2 painkillers, Celebrex and Bextra, have also been linked to higher risks of heart problems.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.